Profiteering off a Covid vaccine

World of DTC Marketing

SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine.

FDA authorizes Pfizer's coronavirus vaccine for younger teens

Bio Pharma Dive

The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand


Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Optimism on Pfizer COVID vaccine is unwarranted

World of DTC Marketing

You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised.

The Covid-19 vaccine numbers game

World of DTC Marketing

SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine

Pfizer forecasts $26B in coronavirus vaccine revenue this year

Bio Pharma Dive

The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year

FDA authorizes J&J's one-shot coronavirus vaccine

Bio Pharma Dive

The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time

Pfizer set to double weekly production of coronavirus vaccine

Bio Pharma Dive

The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday

UK authorizes AstraZeneca, Oxford coronavirus vaccine, but questions linger

Bio Pharma Dive

The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it

Coronavirus vaccine makers Oxford, Novavax follow up with a promising malaria shot

Bio Pharma Dive

A vaccine co-developed by the U.K. academic center and the Maryland biotech could be the first to meet the WHO's efficacy target for a malaria vaccine

Covid vaccine profits and the strain on supply channels

World of DTC Marketing

SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others.

Pharma erupts as Biden administration backs waiver of vaccine patent rights

Bio Pharma Dive

Easing patent protections, though, isn't likely to translate to an immediate boost in vaccine supply The shift in U.S. policy might not undermine future research as the drug industry claims.

Drugs 257

US calls for pause in J&J coronavirus vaccine rollout after rare blood clotting cases

Bio Pharma Dive

The FDA and CDC recommended halting vaccinations while they investigate six cases of unusual blood clots in women given the company's shot

Vaccine makers prepare response as coronavirus mutations raise alarms

Bio Pharma Dive

So far, both Pfizer's and Moderna's vaccines appear to work against more transmissible variants, but preparation is underway for the day they don't

As COVID-19 becomes a business, vaccine makers confront thorny pricing questions

Bio Pharma Dive

Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots

Flu Vaccine vs. COVID-19 Vaccine

My Local Study

These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on

Merck stops coronavirus vaccine development in surprise setback

Bio Pharma Dive

The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials

Manufacturing mix-up could blunt supply boost from J&J vaccine

Bio Pharma Dive

One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses

COVID-19 vaccine: A hope and prayer?

World of DTC Marketing

QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?”

Biden Backs Suspending Patents on Covid Vaccines

NY Times

pharmaceutical industry, came out in favor of waiving intellectual property protections for coronavirus vaccines. The Biden administration, siding with some world leaders over the U.S.

FDA review supports safety, efficacy of J&J coronavirus vaccine

Bio Pharma Dive

Agency scientists noted the shot's strong protection against severe COVID-19, even for the virus variant first detected in South Africa and known to weaken vaccine potency

Coronavirus vaccine from Pfizer, BioNTech prevents COVID-19, early results show

Bio Pharma Dive

An interim analysis conducted after 94 cases of COVID-19 in Pfizer and BioNTech's large study found their vaccine to be more than 90% effective

Novartis joins Sanofi in aiding manufacture of coronavirus vaccines

Bio Pharma Dive

A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments

COVID 19 vaccine means big money and greed

World of DTC Marketing

QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine

UK to start study testing Pfizer, AstraZeneca vaccines together

Bio Pharma Dive

The government-funded trial will evaluate the effects of mixing vaccines and varying timing between shots

Trials 183

FDA advisers meet to review Pfizer, BioNTech's coronavirus vaccine

Bio Pharma Dive

A panel of vaccine and infectious disease experts will publicly vet the drugmakers' study results on Thursday. Follow the discussion along with BioPharma Dive reporters here

Crucial data on AstraZeneca's vaccine are coming. Here's what we may learn.

Bio Pharma Dive

Results from previous trials have raised questions about the vaccine and how well it works. Data from a large U.S. study could help clear up the confusion

Trials 258

CDC advisers recommend resuming use of J&J vaccine

Bio Pharma Dive

While health officials have documented more cases of a rare blood clotting syndrome associated with J&J's vaccine, a CDC committee supported use of the shot with an added warning

J&J says single dose of coronavirus vaccine 66% effective in large trial

Bio Pharma Dive

The vaccine's efficacy was higher in the U.S., but lower in Latin America and South Africa, where new, more infectious virus variants are circulating

Trials 276

Researchers lay out hypothesis for rare side effect linked to AstraZeneca vaccine

Bio Pharma Dive

The EMA has reiterated the benefits of the shot outweigh the risks, but the safety concerns are another hurdle to the vaccine's rollout in Europe

Will people line up for a COVID-19 vaccine?

World of DTC Marketing

QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. The rush to develop a COVID-19 vaccine is well underway because there are billions of dollars in profits at stake. As I See It COVID Vaccine

Pfizer, BioNTech are first to seek full FDA approval of a coronavirus vaccine

Bio Pharma Dive

The milestone filing could pave the way for the shot's use beyond the pandemic and give employers the legal heft to require vaccination, a key step toward herd immunity in the U.S.

Pfizer, BioNTech's strong results give lift to other coronavirus vaccines

Bio Pharma Dive

But differences between each vaccine could still prove crucial The companies' early success helps validate an industry-wide bet to target the coronavirus' spike protein.

CanSino, Canada abandon plans for a coronavirus vaccine trial

Bio Pharma Dive

Canada was set to help CanSino produce its experimental shot as part of a deal to run what would've been the country's first coronavirus vaccine study

Trials 283

Moderna watches for 'waning immunity' as new data show durable vaccine protection

Bio Pharma Dive

Updated study results show Moderna's coronavirus vaccine was strongly protective against COVID-19 through six months. But executives outlined contingency plans in case those effects fade

US secures 200 million more vaccine doses from Pfizer, Moderna

Bio Pharma Dive

would have enough doses to vaccinate 300 million Americans by the end of the July With the orders now finalized, President Biden said the U.S.

AstraZeneca, Oxford vaccine study allowed to restart in UK

Bio Pharma Dive

study participant led to a worldwide pause in vaccinations, the country's drugs regulator and an independent committee allowed testing to resume Six days after a worrisome illness in a U.K.

The US paused use of J&J's vaccine. What happens next?

Bio Pharma Dive

A call by regulators to stop J&J vaccinations won't dramatically disrupt supply in the U.S. But changes in labeling are possible, as is a renewed debate over vaccine hesitancy

A general influenza vaccine


Credit: Dennis Horvath, University of Konstanz One shot, protected forever: This would be a dream come true regarding influenza vaccinations. So far, vaccination against influenza did not provide a lasting protection.

Vaccine sales driven down by pandemic's effects on doctor visits

Bio Pharma Dive

Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations

In milestone, FDA clears coronavirus vaccine from Pfizer, BioNTech for emergency use

Bio Pharma Dive

Vaccinations are expected to begin within days of the historic decision, which follows early approvals in the U.K., Canada and Mexico

Pfizer positions COVID vaccine as a yearly booster shot

World of DTC Marketing

QUICK READ: Pfizer is already positioning their Covid vaccine as a yearly maintenance shot. Make no mistake; the drug companies will make a lot of money from these vaccines while they continue to hide profits offshore. ( If Pfizer raised the price of its coronavirus vaccine from $19.50

Pfizer says coronavirus vaccine study still on track for October readout

Bio Pharma Dive

Importantly, the study committee hasn't had reason to pause vaccinations in the trial, something AstraZeneca and the University of Oxford recently reported in tests of their vaccine

Trials 273

Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine doses

Bio Pharma Dive

The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 100 million doses of Pfizer and BioNTech's vaccine for supply in Europe